Sanofi (France)

Could an arthritis medication show promise as a treatment for the symptoms related to the coronavirus? That’s what Regeneron and Sanofi intend to find out.

As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.

This approval marks the first time in a decade Sanofi has had a wholly-owned cancer drug approved.

The active component of the drug, sodium valproate, has been on the market for epilepsy and bipolar disorder since 1967.

It was another busy week for clinical trial updates. Here’s a look.

No treatments are currently approved for the disease.

The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.

It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.

Despite having one of the best-selling insulin products on the market, Sanofi is exiting diabetes and cardiovascular research and development in favor of more lucrative areas, particularly cancer research.